ABSTRACT
Systemic toxicity currently prevents exploiting the huge potential of many cytokines for medical applications. Here we present a novel strategy to engineer immunocytokines with very high targeting efficacies. The method lies in the use of mutants of toxic cytokines that markedly reduce their receptor-binding affinities, and that are thus rendered essentially inactive. Upon fusion to nanobodies specifically binding to marker proteins, activity of these cytokines is selectively restored for cell populations expressing this marker. This 'activity-by-targeting' concept was validated for type I interferons and leptin. In the case of interferon, activity can be directed to target cells in vitro and to selected cell populations in mice, with up to 1,000-fold increased specific activity. This targeting strategy holds promise to revitalize the clinical potential of many cytokines.
Subject(s)
Cytokines/metabolism , Drug Delivery Systems , Leptin/metabolism , Receptors, Cytokine/metabolism , Single-Domain Antibodies/metabolism , Animals , Humans , Interferon Type I/metabolism , Interferon-alpha/metabolism , Interleukin-15/metabolism , Interleukin-2/metabolism , Mice , Protein Binding , Receptor, Interferon alpha-beta/metabolism , Receptors, Leptin , Receptors, Tumor Necrosis Factor, Type I/metabolismABSTRACT
In living color: efficient intracellular covalent labeling of proteins with a photoswitchable dye using the HaloTag for dSTORM super-resolution imaging in live cells is described. The dynamics of cellular nanostructures at the plasma membrane were monitored with a time resolution of a few seconds. In combination with dual-color FPALM imaging, submicroscopic receptor organization within the context of the membrane skeleton was resolved.